Research programme: cancer therapies - Daewoong Pharmaceutical
Alternative Names: carcinostatis substance - DaewoongLatest Information Update: 16 Jul 2016
At a glance
- Originator Daewoong Pharmaceutical
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in South Korea
- 22 Apr 2009 Early research in Cancer in South Korea (unspecified route)